Study guide

7.2 Cardiovascular & Gastrointestinal Therapeutics

PSI Equivalence Examination Third Country Qualification Recognition

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & TCQR Framework

1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment

2 Chapter 2: Pharmaceutical Calculations

2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions

3 Chapter 3: Pharmacology & Applied Pharmacokinetics

3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs

4 Chapter 4: Basic Science & Pharmaceutics

4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence

5 Chapter 5: Pharmacy Practice & Dispensing Workflow

5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services

6 Chapter 6: Irish Pharmacy Law & Professional Ethics

6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct

7 Chapter 7: Clinical Therapeutics & Disease State Management

7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care

8 Chapter 8: OSCE & Practical Clinical Communication Skills

8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement

7.2 Cardiovascular & Gastrointestinal Therapeutics

Key Takeaways Explain This Topic AI

Hypertension management follows step-wise ESC/NICE pathways based on age and ethnicity, utilizing A+C or A+D combinations.

HFrEF survival depends on the 4 foundational pillars: ARNI/ACEi/ARB, evidence-based Beta-blocker, MRA, and SGLT2 inhibitor.

Switching from an ACE inhibitor to Sacubitril/Valsartan (ARNI) strictly requires a 36-hour washout period to prevent life-threatening angioedema.

Atrial fibrillation stroke risk stratification via CHA2DS2-VASc dictates DOAC therapy, which is preferred over Warfarin except in mechanical heart valves.

H. pylori eradication requires triple therapy (PPI + Amoxicillin + Clarithromycin), while red flag GI symptoms (ALARM) demand urgent endoscopy.

Last updated: July 2026

7.2 Cardiovascular & Gastrointestinal Therapeutics

Cardiovascular and gastrointestinal disorders represent a major proportion of primary care presentation and inpatient pharmacotherapy. This section provides an in-depth review of evidence-based management for hypertension, heart failure with reduced ejection fraction (HFrEF), atrial fibrillation (AF), peptic ulcer disease (PUD), gastro-oesophageal reflux disease (GERD), and inflammatory bowel disease (IBD).

Hypertension Management (ESC & NICE Guidelines)

Diagnosis and treatment of hypertension depend on accurate Blood Pressure (BP) classification across clinic and ambulatory/home settings.

BP Thresholds & Definitions

Stage 1 Hypertension: Clinic BP >=140/90 mmHg AND Subsequent ABPM/HBPM average >=135/85 mmHg.

Stage 2 Hypertension: Clinic BP >=160/100 mmHg AND Subsequent ABPM/HBPM average >=150/95 mmHg.

Stage 3 (Severe) Hypertension: Clinic SBP >=180 mmHg OR Clinic DBP >=110 mmHg. NICE HYPERTENSION TREATMENT ALGORITHM

======================================

  • Step 1: Patient Selection
  • ├── Aged < 55 years OR Type 2 Diabetes ───────> ACEi or ARB (Step 1 A)
  • └── Aged >= 55 years OR Black African/Carib ─> CCB (Step 1 C)
  • |
  • Step 2: Combination Therapy
  • └── Combine A + C (ACEi/ARB + CCB)
  • OR Combine A + D (ACEi/ARB + Thiazide-like Diuretic, e.g., Indapamide)
  • |
  • Step 3: Triple Therapy
  • └── Combine A + C + D (ACEi/ARB + CCB + Thiazide-like Diuretic)
  • |
  • Step 4: Resistant Hypertension (Confirm with ABPM)
  • ├── Check Serum Potassium (K+)
  • ├── K+ <= 4.5 mmol/L ──> Add Low-Dose Spironolactone (25 mg daily)
  • └── K+ > 4.5 mmol/L ──> Add Alpha-blocker (Doxazosin) or Beta-blocker
  • Heart Failure with Reduced Ejection Fraction (HFrEF)

HFrEF is defined as symptomatic heart failure with Left Ventricular Ejection Fraction (LVEF) <=40% . Pharmacotherapy centers on mortality reduction via neurohormonal blockade.

The Four Foundational Pillars of HFrEF Therapy

All four drug classes should be initiated and uptitrated rapidly to target doses as tolerated:

ARNI / ACEi / ARB:

Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/Valsartan is preferred over ACEi/ARB to reduce mortality and hospitalizations.

CRITICAL SAFETY RULE: When switching a patient from an ACE inhibitor to Sacubitril/Valsartan, a mandatory 36-hour washout period must be observed to avoid accumulation of bradykinin causing fatal angioedema .

Evidence-Based Beta-Blockers: Bisoprolol, Carvedilol, or Nebivolol. Start low and titrate slowly once the patient is hemodynamically stable.

Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone or Eplerenone. Requires monitoring of serum potassium and eGFR (risk of hyperkalemia).

SGLT2 Inhibitors: Dapagliflozin or Empagliflozin. Provides mortality benefit independent of glycemic status.

Symptomatic Relief: Loop Diuretics (e.g., Furosemide 20-80 mg daily) are added to control congestion and volume overload, but do not directly confer mortality reduction.

Atrial Fibrillation (AF) & Anticoagulation

AF management requires dual focus: stroke prevention and symptom control (rate vs. rhythm control).

Stroke Risk Stratification: CHA2DS2-VASc Score

  • Criteria Description Points
  • C Congestive Heart Failure / LV dysfunction 1
  • H Hypertension 1
  • A2 Age >= 75 years 2
  • D Diabetes Mellitus 1
  • S2 Stroke / TIA / Thromboembolism history 2
  • V Vascular Disease (prior MI, PAD, aortic plaque) 1
  • A Age 65 - 74 years 1
  • Sc Sex Category (Female) 1

Anticoagulation Guidance:

Score >= 2 in Males or >= 3 in Females: Oral Anticoagulation Strongly Recommended .

Score = 1 in Males or = 2 in Females: Consider Oral Anticoagulation.

Score = 0 in Males or = 1 in Females: No Anticoagulation required.

Direct Oral Anticoagulants (DOACs) vs. Warfarin

DOACs (Apixaban, Rivaroxaban, Edoxaban, Dabigatran) are first-line over Warfarin due to superior safety profiles (lower intracranial hemorrhage risk) and lack of routine INR monitoring.

Exception: Warfarin remains mandatory (DOACs contraindicated) in patients with mechanical heart valves or moderate-to-severe mitral stenosis .

Rate vs. Rhythm Control

Rate Control (First-Line for Most): Target resting HR <110 bpm. First-line agents: Beta-blockers (Bisoprolol) or Non-dihydropyridine CCBs (Diltiazem/Verapamil). Contraindication: Non-dihydropyridine CCBs are strictly contraindicated in HFrEF due to negative inotropic effects.

Rhythm Control: Indicated for symptomatic AF despite rate control. Agents include Flecainide (contraindicated in structural/ischemic heart disease) and Amiodarone.

  • Gastro-Oesophageal Reflux (GERD) & Peptic Ulcer Disease (PUD)
  • GERD Step-Wise Escalation & Red Flags

GERD management steps: Lifestyle modification -> Antacids/Alginates -> H2-Receptor Antagonists (Famotidine) -> Proton Pump Inhibitors (PPIs: Omeprazole, Lansoprazole).

PPI Long-Term Risks: Clostridioides difficile infection, hypomagnesaemia, vitamin B12 deficiency, acute interstitial nephritis, and osteoporotic fractures. ALARM RED FLAGS FOR URGENT ENDOSCOPY

===================================

  • A ──> Anemia (iron deficiency)
  • L ──> Loss of weight (unintentional)
  • A ──> Anorexia
  • R ──> Recent onset of progressive dyspepsia in patients aged > 55 years
  • M ──> Melaena or Hematemesis
  • D ──> Dysphagia or Odynophagia
  • Peptic Ulcer Disease & H. pylori Eradication

Helicobacter pylori infection is a major cause of PUD. Eradication requires high-dose triple therapy for 7-14 days.

First-Line Standard Triple Therapy:

PPI (e.g., Omeprazole 20 mg b.i.d.) + Amoxicillin 1 g b.i.d. + Clarithromycin 500 mg b.i.d.

Penicillin-Allergic Regimen:

PPI b.i.d. + Metronidazole 400 mg b.i.d. + Clarithromycin 500 mg b.i.d.

High Clarithromycin Resistance Area / Second-Line: Bismuth Quadruple Therapy (PPI + Bismuth Subsalicylate + Metronidazole + Tetracycline).

Inflammatory Bowel Disease (IBD)

Disease Parameter Ulcerative Colitis (UC) Crohn's Disease (CD)

Anatomical Distribution Mucosal layer; continuous inflammation originating in rectum extending proximally Transmural inflammation; skip lesions anywhere from mouth to anus

First-Line Induction (Mild-Mod) Topical/Oral 5-ASA (Mesalazine) Systemic Corticosteroids (Prednisolone) or Budesonide

Flare Management Oral/IV Corticosteroids (Hydrocortisone/Prednisolone) Oral/IV Corticosteroids

Maintenance Therapy 5-ASA (Mesalazine), Thiopurines (Azathioprine), Biologics Thiopurines (Azathioprine), Methotrexate, Biologics

Safety Check: Prior to starting Azathioprine or Mercaptopurine , test for Thiopurine S-methyltransferase (TPMT) activity. Deficiency of TPMT leads to severe, potentially fatal bone marrow toxicity due to toxic thioguanine metabolite accumulation.